JAK inhibitors and tocilizumab elicit better response rates in VEXAS syndrome

https://www.news-medical.net/news/20231107/JAK-inhibitors-and-tocilizumab-elicit-better-response-rates-in-VEXAS-syndrome.aspx VEXAS syndrome is a rare and often fatal autoimmune condition caused by a mutation in the UBA1 gene.